演題詳細

ポスター / Poster

ポスター 38 (Poster 38) :血栓症・その他 (Thrombosis and Others)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
小嶋 哲人 (Tetsuhito Kojima):1
1:名古屋大学大学院医学系研究科
 
前へ戻る

VerifyNow™ P2Y12 parameters in non-drug users

演題番号 : PS-1-288

Yun-A Jo:1、Young Kyung Lee:1、Hee Jung Kang:2、Han-Sung Kim:3

1:Department of Laboratory Medicine, Hallym University College of Medicine, Korea

 

Background : VerifyNow™ P2Y12 (Accumetrics, San Diego, CA, USA), a widely used platelet function test for monitoring clopidogrel, reports 2 parameters, % inhibition and PRU. Little is known about the effectiveness of each parameter when it comes to indicating drug response. Furthermore, the criteria of responsiveness are not clearly defined because there is no data about the distribution of each parameter in non-drug users. Thus, we intend to analyze the distribution of % inhibition and PRU in non-drug users.
Methods : We analyzed 169 patients who have not taken clopidogrel within 1 month and 125 patients who are taking clopidogrel for more than 1 week. Platelet function was measured by VerifyNow™ P2Y12 assay using sodium citrated whole blood. Drug history was reviewed through electronic medical record.
Results : % inhibition was negatively correlated with PRU (r=-0.82, P<0.001). Among 169 non-drug users, 115 patients (68%) showed 0% inhibition, and 37 patients (21.9%) showed 0~10% inhibition. No patients showed >40% inhibition. 54 of the patients with clopidogrel (35.2%) showed <20% inhibition. PRU was lower in drug users (297.6±55.5, mean±SD) than in non drug users (216.0±68.2, mean±SD) (P<0.001). In ROC analysis, the cut-off value for discrimination of drug use was 9.5% inhibition (sensitivity 0.85, specificity 0.12; AUC 0.925) and 274.5 PRU (sensitivity 0.80, specificity 0.29; AUC 0.828).
Conclusions : Our results suggested that % inhibition is the better indicator to discriminate between non-drug users and drug users Among non-drug users, 88% were <9.5% inhibition and 71% were >274.5 PRU. To estimate clinically significant cut off value to determine drug responsiveness, further study in which the relationship with the parameter and thrombotic event is analyzed should be conducted.

前へ戻る